Analysts expect that Halozyme Therapeutics, Inc. (NASDAQ:HALO) will post earnings of $0.60 per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Halozyme Therapeutics’ earnings, with the lowest EPS estimate coming in at $0.53 and the highest estimate coming in at $0.71. Halozyme Therapeutics reported earnings of ($0.21) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 385.7%. The firm is scheduled to issue its next quarterly earnings report on Tuesday, February 27th.

On average, analysts expect that Halozyme Therapeutics will report full-year earnings of $0.20 per share for the current financial year, with EPS estimates ranging from $0.06 to $0.34. For the next fiscal year, analysts expect that the company will post earnings of ($0.74) per share, with EPS estimates ranging from ($1.07) to ($0.45). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Halozyme Therapeutics.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.04). Halozyme Therapeutics had a negative return on equity of 892.57% and a negative net margin of 53.17%. The company had revenue of $63.73 million during the quarter, compared to the consensus estimate of $58.95 million. During the same quarter in the prior year, the firm earned ($0.23) earnings per share. The business’s revenue was up 100.1% compared to the same quarter last year.

HALO has been the subject of a number of research analyst reports. Zacks Investment Research upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $22.00 price target for the company in a research note on Tuesday, December 12th. Canaccord Genuity lifted their price target on shares of Halozyme Therapeutics from $17.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, November 8th. Barclays lowered shares of Halozyme Therapeutics from an “overweight” rating to a “hold” rating and lifted their price target for the stock from $16.00 to $19.00 in a research note on Wednesday, November 22nd. BMO Capital Markets lifted their price target on shares of Halozyme Therapeutics from $15.00 to $18.00 and gave the stock a “market perform” rating in a research note on Wednesday, November 8th. Finally, BidaskClub lowered shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 5th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $19.14.

Shares of Halozyme Therapeutics (HALO) opened at $19.74 on Wednesday. Halozyme Therapeutics has a 12 month low of $10.74 and a 12 month high of $21.13. The company has a market cap of $2,800.00, a P/E ratio of -29.03 and a beta of 2.09. The company has a quick ratio of 3.37, a current ratio of 3.46 and a debt-to-equity ratio of 2.01.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Arrowstreet Capital Limited Partnership purchased a new position in shares of Halozyme Therapeutics in the second quarter worth approximately $131,000. Prudential Financial Inc. boosted its holdings in shares of Halozyme Therapeutics by 8.7% in the second quarter. Prudential Financial Inc. now owns 11,726 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 940 shares during the last quarter. 361 Capital LLC purchased a new position in shares of Halozyme Therapeutics in the third quarter worth approximately $207,000. Trexquant Investment LP purchased a new position in shares of Halozyme Therapeutics in the third quarter worth approximately $224,000. Finally, Los Angeles Capital Management & Equity Research Inc. purchased a new position in shares of Halozyme Therapeutics in the third quarter worth approximately $227,000. 84.45% of the stock is currently owned by institutional investors.

WARNING: “$0.60 Earnings Per Share Expected for Halozyme Therapeutics, Inc. (HALO) This Quarter” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/17/0-60-earnings-per-share-expected-for-halozyme-therapeutics-inc-halo-this-quarter.html.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Get a free copy of the Zacks research report on Halozyme Therapeutics (HALO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.